Episode 36: Sofinnova Invetments' Jim Healy
BioVenture VoiCes with Chris Garabedian
00:00
Modality preferences and biologics bias
Jim prefers biologics for higher clinical success, and highlights ADCs, targeted radiotherapeutics, gene and RNA technologies.
Play episode from 54:51
Transcript
